Practical considerations in the pharmacologic treatment of idiopathic pulmonary fibrosis
Authors:
- Steven D. NathanSNSteven D. Nathan
- 1 September 2015
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Pulmonary Medicine
- Vol. 21 (5) , 479-489
Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive and deadly disease. The US Food and Drug Administration recently approved two medications for the treatment of IPF – pirfenidone and nintedanib. Given the limited clinical experience with these agents, a number of questions remain regarding their use. Both pirfenidone and nintedanib were demonstrated to reduce the rate of decline in forced vital capacity in independent large, double-blind, randomized controlled clinical trials. The successful implementation of both agents in clinical practice is dependent on many factors, including which patients to prescribe them in and managing patient expectations regarding efficacy and side effects. Pirfenidone is frequently associated with gastrointestinal upset, malaise, and rash. Nintedanib often causes diarrhea. Both drugs may cause elevations in liver-associated enzymes and require serial monitoring. Despite the side effects mentioned, these drugs are generally well tolerated in the long term. It should be emphasized to patients that these drugs do not represent a ‘cure’ for IPF and that the goal of therapy is stabilization of their disease. Currently many questions remain regarding the use of pirfenidone and nintedanib in IPF, including which drug to prescribe, the optimal patient population to treat, the duration of therapy, and how to define treatment success or failure. It also remains to be seen whether combination therapy with both agents will result in improved outcomes. Hopefully, future randomized controlled trials will address these issues.Keywords
This publication has 30 references indexed in Scilit:
- Pharmacological treatment of idiopathic pulmonary fibrosis: an updateDrug Discovery Today, 2015
- Forced Vital Capacity in Idiopathic Pulmonary Fibrosis — FDA Review of Pirfenidone and NintedanibNew England Journal of Medicine, 2015
- Pirfenidone: A Review of Its Use in Idiopathic Pulmonary FibrosisDrugs, 2015
- New Therapeutic Targets in Idiopathic Pulmonary Fibrosis. Aiming to Rein in Runaway Wound-Healing ResponsesAmerican Journal of Respiratory and Critical Care Medicine, 2014
- Randomized Trial of Acetylcysteine in Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 2014
- A Placebo-Controlled Randomized Trial of Warfarin in Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2012
- Unravelling the progressive pathophysiology of idiopathic pulmonary fibrosisEuropean Respiratory Review, 2012
- Prednisone, Azathioprine, andN-Acetylcysteine for Pulmonary FibrosisNew England Journal of Medicine, 2012
- Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trialThe Lancet, 2009
- Idiopathic Pulmonary Fibrosis: Prevailing and Evolving Hypotheses about Its Pathogenesis and Implications for TherapyAnnals of Internal Medicine, 2001